LUNG
PULMONX CORP
1 day chart
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solutions include Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), which is designed to treat severe emphysema patients. Its solutions provide bronchoscopic lung volume reduction without surgery. Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape. The StratX Platform is used to identify patients eligible for treatment with Zephyr Valves. It operates in North America, Europe and Asia Pacific.
Buy US stocks in Australia with $0 brokerage and trade LUNG today!
$635.80M
-
0.00%
40.91K
$17.49
$16.82
$16.82
$45.49
$13.79
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.